Kite nails down TCR IP in new licensing pact

John Carroll

Pharma has moved to cement its control of some of the IP behind its work on T cell receptor-based product candidates that zero in on MAGE A3 and A3/A6 antigens.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS